ProImmune Ltd. has launched a new special assay service providing custom immunological assays based its platform technologies. ProImmune developed the service as a result of companies seeking modified versions of its range of immunology platform assays to suit specific needs. According to the company, its standard assays can be readily adapted to meet the customer’s requirements, and therefore deployed rapidly, enabling fast implementation of unique protocols.

ProImmune’s existing immunology assay services include immune modulation assays, managing drug immunogenicity risk, characterizing the immune response to new antigens, and a wide range of immune monitoring assays.

Dr. Nikolai Schwabe, chief executive officer of ProImmune, said, “The introduction of the Special Assay Service highlights the evolution of assay customization into a formal discipline within the company, and demonstrates our commitment to delivering the most innovative and comprehensive service available for characterizing immune responses. As with our standard assays, our technically-trained customer service staff is able to understand the core objectives and issues in a project from the outset and are committed to rapidly providing detailed proposals to our customers’ RFPs.”